Sfoglia per AUTORE
MURGIONI S
Collezione AO Cuneo
Items : 2
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. in The Lancet. Oncology / Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.
2020
AO Cuneo
AOU Città della Salute di Torino
AO Cuneo
AOU Città della Salute di Torino
Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Falcone A; Boni L; Zagonel V; Ugolini C; Fontanini G; Corgna E; Cupini S; Mammoliti S; Fenocchio E; Roselli M; Mambrini A; Ritorto G; Di Donato S; Clavarezza M; Carlomagno C; Ronzoni M; Tomasello G; Masi G; Antonuzzo L; Cordio S; Moretto R; Corallo S; Granetto C; Buonadonna A; Zaniboni A; et alii...
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2019 Mar;109:175-182. doi: 10.1016/j.ejca.2018.12.028. Epub 2019 Feb 5.
2019
AO Cuneo
AO Cuneo
Lonardi S; Sensi E; Tonini G; Di Donato S; Schirripa M; Delfanti S; Granetto C; Gemma D; Casagrande M; Borelli B; Allegrini G; Murgioni S; Antoniotti C; Dell'Aquila E; Salvatore L; Masi G; Aprile G; Bergamo F; Cremolini C; Marmorino F; Fontanini G; Boni L; Falcone A;